Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 11, 2009, Pages 1374-1375

  Benešová, Yvonne ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GADOLINIUM; GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

BLOOD SAMPLING; CEREBROSPINAL FLUID LEVEL; DISEASE MARKER; HUMAN; LETTER; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN TARGETING;

EID: 70450178100     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509348421     Document Type: Letter

References (8)

1. Jung K., Klotzek S., Stephan C., Mannello F., Lein M. Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. Clin Chem 2008; 54: 772-774.
2. Mannello F., Jung K., Tonti GA, Canestrari F. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin Biochem 2008; 41: 1466-1473.
3. Meisser A., Cohen M., Bischof P. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem 2005; 51: 274-276.
4. Fainardi E., Castellazzi M., Bellini T., Dallocchio F. Matrix metalloproteinases (MMP): Determination of different forms by different techniques may require different preanalytical strategies. Mult Scler 2007; 13: 691-692.
5. Avolio C., Ruggieri M., Giuliani F., et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136: 46-53.
6. Liuzzi GM, Trojano M., Fanelli M., et al. Intrathecal synthesis of matrixmetalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 2002; 8: 222-228.
7. Waubant E., Goodkin DE, Gee L., et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999; 53: 1397-1401.
8. Waubant E., Goodkin D., Bostrom A., et al. IFN beta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003; 60: 52-57.